Skip to main content
. 2020 Oct 1;6(10):e05087. doi: 10.1016/j.heliyon.2020.e05087

Table 2.

The relationship between MCM2 and clinicopathological features of breast cancer.

Type of samples Expression of mRNA∗ Number of samples Cox P-value
Normal 114
Tumor 1097 1.62E-12

Individual cancer stages
Normal 114
Stage 1 183 <1E-12
Stage 2 615 1.62E-12
Stage 3 247 1.62E-12
Stage 4

20
1.54E-04
Patient's race
Normal 114
Caucasian 748 1.62E-12
African American 179 <1E-12
Asian

61
6.65E-10
Patient's gender
Normal 114
Male 12 2.20E-03
Female

1075
1.60E-12
Patient's age
Normal 114
21-40 Yrs 97 1.62E-12
41-60 Yrs 505 1.62E-12
61-80 Yrs 431 1.11E-16
81-100 Yrs

54
4.62E-06
Major subclasses
Normal 114
Luminal 566 1.62E-12
HER2 positive 37 1.52E-07
Triple-negative

116
1.62E-12
Major subclasses (incl. TNBC type)
Normal 114
Luminal 566 1.62E-12
HER2pos 37 1.52E-07
TNBC-BL1 13 2.74E-07
TNBC-BL2 1113 1.98E-04
TNBC-IM 2011 1.25E-06
TNBC-LAR 820 1.11E-01
TNBC-MSL 8 4.70E-03
TNBC-M 29 2.77E-06
TNBC-UNS

27
3.90E-06
Menopause Status
Normal 114
Pre-menopause 230 1.62E-12
Perimenopause 37 5.18E-07
Post-menopause

700
1.62E-12
Tumor histology
Normal 114
IDC 784 <1E-12
ILC 203 1.62E-12
Mixed 29 7.28E-09
Other 45 3.92E-05
Mucinous 17 2.32E-03
Metaplastic 9 1.58E-02
INOS 1 N/A
Medullary

6
6.16E-04
Nodal Metastasis status
Normal 114
NO 516 1.62E-12
N1 362 1.62E-12
N2 120 <1E-12
N3 77 2.26E-12

∗Down-arrow (↓) indicates the underexpression while up-arrow (↑) indicates the overexpression.